Glyn Edwards takes chairman role at UK oncolytic virus startup emerging out of stealth

Paul Schloesser

Associate Editor

Oncolytic viruses — viruses that can selectively replicate in cancer cells and kill them — have been steadily attracting investment and curiosity. However, for the most part …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Glyn Edwards takes chairman role at UK oncolytic virus startup emerging out of stealth

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Glyn Ed­wards takes chair­man role at UK on­colyt­ic virus start­up emerg­ing out of stealth

Associate Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Glyn Edwards takes chairman role at UK oncolytic virus startup emerging out of stealth